Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder

Schizophrenia Research

Volumn 145, Issue 1-3, 2013, Pages 36-42

  Hope, Sigrun ^a,b   Ueland, Thor ^c,e   Steen, Nils Eiel ^a,b   Dieset, Ingrid ^a,b   Lorentzen, Steinar ^a,b   Berg, Akiah O ^a,b   Agartz, Ingrid ^a,d   Aukrust, Pål ^c,e   Andreassen, Ole A ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d DIAKONHJEMMET HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

IL 1Ra; Immune factors; Inflammation; Psychotic symptoms; Severe mental disorders; Tnfr1

Indexed keywords

ANTIDEPRESSANT AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MOOD STABILIZER; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR RECEPTOR 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOLOGIC TEST; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84875267862     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.12.023     Document Type: Article

References (63)

1. Aas I.M. Global Assessment of Functioning (GAF): properties and frontier of current knowledge. Ann. Gen. Psychiatry 2010, 9:20.
2. Arakawa H., Blandino P., Deak T. Central infusion of interleukin-1 receptor antagonist blocks the reduction in social behavior produced by prior stressor exposure. Physiol. Behav. 2009, 98(1-2):139-146.
3. Belarbi K., Jopson T., Tweedie D., Arellano C., Luo W., Greig N.H., Rosi S. TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J. Neuroinflammation 2012, 9:23.
4. Birkenaes A.B., Opjordsmoen S., Brunborg C., Engh J.A., Jonsdottir H., Ringen P.A., Simonsen C., Vaskinn A., Birkeland K.I., Friis S., Sundet K., Andreassen O.A. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J. Clin. Psychiatry 2007, 68(6):917-923.
5. Bluthâe R.M., Dantzer R., Kelley K.W. Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology 1997, 22(1):1-11.
6. Bollerslev J., Ueland T., Jorgensen A.P., Fougner K.J., Wergeland R., Schreiner T., Burman P. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur. J. Endocrinol. 2006, 154(4):537-543.
7. Brill N., Reichenberg A., Weiser M., Rabinowitz J. Validity of the premorbid adjustment scale. Schizophr. Bull. 2008, 34(5):981-983.
8. Brydon L., Walker C., Wawrzyniak A., Whitehead D., Okamura H., Yajima J., Tsuda A., Steptoe A. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav. Immun. 2009, 23(2):217-224.
9. Burmeister M., McInnis M.G., Zollner S. Psychiatric genetics: progress amid controversy. Nat. Rev. Genet. 2008, 9(7):527-540.
10. Chadwick W., Magnus T., Martin B., Keselman A., Mattson M.P., Maudsley S. Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci. 2008, 31(10):504-511.
11. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26(9):1185-1193.
12. Chen S.J., Chao Y.L., Chen C.Y., Chang C.M., Wu E.C., Wu C.S., Yeh H.H., Chen C.H., Tsai H.J. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br. J. Psychiatry 2012, 200(5):374-380.
13. Chen S.L., Lee S.Y., Chang Y.H., Chen S.H., Chu C.H., Tzeng N.S., Lee I.H., Chen P.S., Yeh T.L., Huang S.Y., Yang Y.K., Lu R.B. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J. NeuroImmune Pharm. 2012, 7(3):656-664.
14. Clerici M., Arosio B., Mundo E., Cattaneo E., Pozzoli S., Dell'osso B., Vergani C., Trabattoni D., Altamura A.C. Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectr. 2009, 14(8):419-425.
15. Diez-Ruiz A., Tilz G.P., Zangerle R., Baier-Bitterlich G., Wachter H., Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol. 1995, 54(1):1-8.
16. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67(5):446-457.
17. Drexhage R., Knijff E., Padmos R., Heul-Nieuwenhuijzen L., Beumer W., Versnel M., Drexhage H. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert. Rev. Neurother. 2010, 10(1):59-76.
18. Drexhage R.C., Weigelt K., van Beveren N., Cohen D., Versnel M.A., Nolen W.A., Drexhage H.A. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int. Rev. Neurobiol. 2011, 101:169-201.
19. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 2006, 20(6):532-545.
20. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010, 12(6):638-646.
21. Eberhard J., Levander S., Lindstrom E. Remission in schizophrenia: analysis in a naturalistic setting. Compr. Psychiatry 2009, 50(3):200-208.
22. Erbaægci A.B., Herken H., Kèoylèuoglu O., Yilmaz N., Tarak{eth}cioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediat. Inflamm. 2001, 10(3):109-115.
23. Freudenreich O., Brockman M.A., Henderson D.C., Evins A.E., Fan X., Walsh J.P., Goff D.C. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 2010, 176(2-3):99-102.
24. Gabay C., Smith M.F., Eidlen D., Arend W.P. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J. Clin. Invest. 1997, 99(12):2930-2940.
25. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70(8):1078-1090.
26. Gomez-Santos C., Francisco R., Gimenez-Xavier P., Ambrosio S. Dopamine induces TNFalpha and TNF-R1 expression in SH-SY5Y human neuroblastoma cells. NeuroReport 2007, 18(16):1725-1728.
27. Goodwin F.K., Jamison K.R. Manic-depressive Illness 1990, Oxford University Press, New York.
28. Greenberg G.A., Rosenheck R.A. Using the GAF as a national mental health outcome measure in the Department of Veterans Affairs. Psychiatr. Serv. 2005, 56(4):420-426.
29. Gu Y., Zeleniuch-Jacquotte A., Linkov F., Koenig K.L., Liu M., Velikokhatnaya L., Shore R.E., Marrangoni A., Toniolo P., Lokshin A.E., Arslan A.A. Reproducibility of serum cytokines and growth factors. Cytokine 2009, 45(1):44-49.
30. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2005, 10(1):40-68. (image 45).
31. Hope S., Melle I., Aukrust P., Steen N.E., Birkenaes A.B., Lorentzen S., Agartz I., Ueland T., Andreassen O.A. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 2009, 11(7):726-734.
32. Hope S., Melle I., Aukrust P., Agartz I., Lorentzen S., Steen N.E., Djurovic S., Ueland T., Andreassen O.A. Osteoprotegerin levels in patients with severe mental disorders. J. Psychiatry Neurosci. 2010, 35(5):304-310.
33. Hope S., Dieset I., Agartz I., Steen N.E., Ueland T., Melle I., Aukrust P., Andreassen O.A. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatr. Res. 2011, 45(12):1608-1616.
34. Hsuchou H., Kastin A.J., Mishra P.K., Pan W. C-reactive protein increases bbb permeability: implications for obesity and neuroinflammation. Cell. Physiol. Biochem. 2012, 30(5):1109-1119.
35. Jabben N., Arts B., Krabbendam L., van Os J. Investigating the association between neurocognition and psychosis in bipolar disorder: further evidence for the overlap with schizophrenia. Bipolar Disord. 2009, 11(2):166-177.
36. Jiang H., Hampel H., Prvulovic D., Wallin A., Blennow K., Li R., Shen Y. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol. Neurodegener. 2011, 6:69.
37. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
38. Kop W.J., Weissman N.J., Zhu J., Bonsall R.W., Doyle M., Stretch M.R., Glaes S.B., Krantz D.S., Gottdiener J.S., Tracy R.P. Effects of acute mental stress and exercise on inflammatory markers in patients with coronary artery disease and healthy controls. Am. J. Cardiol. 2008, 101(6):767-773.
39. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation 2008, 5:8.
40. Kunz M., Cereser K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011, 33(3):268-274.
41. Mata I., Crespo-Facorro B., Pâerez-Iglesias R., Carrasco-Marâin E., Arranz M.J., Pelayo-Terâan J.M., Leyva-Cobâian F., Vâazquez-Barquero J.L. Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment. American journal of medical genetics. Part B: Neuropsychiatr. Genet. 2006, 141B(8):939-943.
42. McAfoose J. Evidence of a cytokine model for cognitive function. Neurosci. Biobehav. Rev. 2009, 33(3):355-366.
43. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
44. Nahman S., Belmaker R.H., Azab A.N. Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immun. 2012, 18(3):447-458.
45. Norman G.J., Karelina K., Morris J.S., Zhang N., Cochran M., Courtney DeVries A. Social interaction prevents the development of depressive-like behavior post nerve injury in mice: a potential role for oxytocin. Psychosom. Med. 2010, 72(6):519-526.
46. Orre I.J., Murison R., Dahl A.A., Ueland T., Aukrust P., Fossêa S.D. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav. Immun. 2009, 23(6):868-874.
47. Prasad K.M., Eack S.M., Keshavan M.S., Yolken R.H., Iyengar S., Nimgaonkar V.L. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. Schizophr. Bull. 2012, (Epub ahead of print).
48. Prata D.P., Mechelli A., Fu C.H., Picchioni M., Kane F., Kalidindi S., McDonald C., Howes O., Kravariti E., Demjaha A., Toulopoulou T., Diforti M., Murray R.M., Collier D.A., McGuire P.K. Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. Biol. Psychiatry 2009, 65(6):473-480.
49. Rafiq S., Stevens K., Hurst A.J., Murray A., Henley W., Weedon M.N., Bandinelli S., Corsi A.M., Guralnik J.M., Ferruci L., Melzer D., Frayling T.M. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun. 2007, 8(4):344-351.
50. Ringen P.A., Melle I., Birkenaes A.B., Engh J.A., Faerden A., Jonsdottir H., Nesvag R., Vaskinn A., Friis S., Larsen F., Opjordsmoen S., Sundet K., Andreassen O.A. Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr. Scand. 2008, 117(2):133-138.
51. Rohleder N., Wolf J.M., Herpfer I., Fiebich B.L., Kirschbaum C., Lieb K. No response of plasma substance P, but delayed increase of interleukin-1 receptor antagonist to acute psychosocial stress. Life Sci. 2006, 78(26):3082-3089.
52. Santor D.A., Ascher-Svanum H., Lindenmayer J.P., Obenchain R.L. Item response analysis of the Positive and Negative Syndrome Scale. BMC Psychiatry 2007, 7:66.
53. Schmitt A., Bertsch T., Tost H., Bergmann A., Henning U., Klimke A., Falkai P. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr. Dis. Treat. 2005, 1(2):171-177.
54. Sirota P., Meiman M., Herschko R., Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res. 2005, 134(2):151-159.
55. Sommer I.E., de Witte L., Begemann M., Kahn R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J. Clin. Psychiatry 2012, 73(4):414-419.
56. Spulber S., Mateos L., Oprica M., Cedazo-Minguez A., Bartfai T., Winblad B., Schultzberg M. Impaired long term memory consolidation in transgenic mice overexpressing the human soluble form of IL-1ra in the brain. J. Neuroimmunol. 2009, 208(1-2):46-53.
57. Tchelingerian J.L., Quinonero J., Booss J., Jacque C. Localization of TNF alpha and IL-1 alpha immunoreactivities in striatal neurons after surgical injury to the hippocampus. Neuron 1993, 10(2):213-224.
58. Vistoropsky Y., Ermakov S., Toliat M.R., Trofimov S., Altmuller J., Malkin I., Nurnberg P., Livshits G. Genetic determinants of circulating levels of tumor necrosis factor receptor II and their association with TNF-RII gene polymorphisms. Cytokine 2010, 51(1):28-34.
59. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010, 64(3):217-230.
60. Williams H.J., Craddock N., Russo G., Hamshere M.L., Moskvina V., Dwyer S., Smith R.L., Green E., Grozeva D., Holmans P., Owen M.J., O'Donovan M.C. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum. Mol. Genet. 2011, 20(2):387-391.
61. Wirgenes K.V., Djurovic S., Sundet K., Agartz I., Mattingsdal M., Athanasiu L., Melle I., Andreassen O.A. Catechol O-methyltransferase variants and cognitive performance in schizophrenia and bipolar disorder versus controls. Schizophr. Res. 2010, 122(1-3):31-37.
62. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 2011, 25(2):181-213.
63. Zhang X.Y., Cao L.Y., Song C., Wu G.Y., Chen da C., Qi L.Y., Wang F., Xiu M.H., Chen S., Zhang Y., Lu L., Kosten T.A., Kosten T.R. Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology 2008, 201(3):383-389.